Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Blood (2024) 144 (Supplement 1): 684.

https://doi.org/10.1182/blood-2024-206163

Published: 2024

Journal Articles

Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience

Blood (2024) 144 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2024-207051

Published: 2024

Journal Articles

Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion

Blood (2023) 142 (Supplement 1): 1605.

https://doi.org/10.1182/blood-2023-180355

Published: 2023

Journal Articles

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Krauss, Arend von Stackelberg, Semjon Willier, Christina Peters, Tobias Feuchtinger

Blood (2023) 142 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2023-190117

Published: 2023

Journal Articles

Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML

Frederic Millot, Joe De Keizer, Markus Metzler, Meinolf Suttorp, Petr Sedlacek, Maaike Luesink, Frankie WT Cheng, Krzysztof Kalwak, Birgitte Lausen, Gordana Jakovljevic, Barbara De Moerloose, Michael Dworzak, Marina Borisevich, Julia Yajima, Mirella Ampatzidou, Roula Farah, Emilia Kaiserova, Adalet Meral Günes, Andre Baruchel

Blood (2023) 142 (Supplement 1): 448.

https://doi.org/10.1182/blood-2023-173810

Published: 2023

Journal Articles

Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response

Franziska Gsottberger, Christina Meier, Anna Ammon, Scott Parker, Kerstin Wendland, Rebekka George, Srdjan Petkovic, Lisa Mellenthin, Charlotte Emmerich, Gloria Lutzny-Geier, Markus Metzler, Andreas Mackensen, Vidyalakshmi Chandramohan, Fabian Mueller

Blood (2022) 140 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2022-169012

Published: 2022

Journal Articles

Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation

Nina Eisenhauer, Maurizio Miano, Nora Naumann-Bartsch, Joerg Leyh, Paola Terranova, Claas Hinze, Michael Aigner, Helmut Wittkowski, Heiko Bruns, Stephan Ehl, Markus Metzler, Peter Arkwright, Andreas Mackensen, Anne Rensing-Ehl, Simon Voelkl

Blood (2022) 140 (Supplement 1): 11194.

https://doi.org/10.1182/blood-2022-168550

Published: 2022

Journal Articles

The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13

Blood (2021) 138 (19): 1870–1884.

https://doi.org/10.1182/blood.2021011557

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

Blood (2021) 138 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2021-145709

Published: 2021

Journal Articles

High Platelet Counts, Thrombosis, Bleeding Signs, and Acquired Von Willebrand Syndrome at Diagnosis of Pediatric Chronic Myeloid Leukemia

Meinolf Suttorp, MD PhD, Ralf Knoefler, MD PhD, Hélène Deutsch, MD, Franziska Paul, cand. MD, Oliver Tiebel, MD, Markus Metzler, MD PhD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4152.

https://doi.org/10.1182/blood-2019-123343

Published: 2019

Journal Articles

Vaccination with Live Attenuated Virus Vaccines in Four Pediatric Patients with CML While on Imatinib Treatment

Claudia Bettoni Da Cunha-Riehm, MD, Verena Hildebrand, MD, Michaela Nathrath, MD PhD, Markus Metzler, MD PhD, Meinolf Suttorp, MD PhD

Blood (2019) 134 (Supplement_1): 5903.

https://doi.org/10.1182/blood-2019-122219

Published: 2019

Journal Articles

The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression

Costanza Zanetti, MSc, Joscha Ender, Mark Hartmann, Joschka Hey, MSc, BSc, Parimala Sonika Godavarthy, MSc, Eva Weissenberger, Rahul Kumar, PhD, Markus Metzler, MD PhD, Zhaohui Gu, PhD, Kathryn G. Roberts, PhD, Natalie Filmann, Clara D. Bloomfield, MD, Wendy Stock, MD, Charles G. Mullighan, MBBS, MD, Daniel B. Lipka, Daniela S. Krause, MD

Blood (2019) 134 (Supplement_1): 2748.

https://doi.org/10.1182/blood-2019-122797

Published: 2019

Journal Articles

The preleukemic TCF3 -PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

Daniel Hein, Karin Dreisig, Markus Metzler, Shai Izraeli, Kjeld Schmiegelow, Arndt Borkhardt, Ute Fischer

Blood (2019) 134 (16): 1355–1358.

https://doi.org/10.1182/blood.2019002215

Published: 2019

Includes: Supplemental data

Journal Articles

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Blood (2017) 130 (Supplement 1): 898.

https://doi.org/10.1182/blood.V130.Suppl_1.898.898

Published: 2017

Journal Articles

Nivolumab As Salvage Therapy in Pediatric Patients with Relapsed and Refractory Lymphomas

Nora Naumann-Bartsch, MD, Daniel Stachel, MD, Martin Chada, MD, Torsten Fritscher, MD, Oliver Rompel, MD, Florian Haller, MD, Arndt Hartmann, MD, Wilhelm Wößmann, MD, Markus Metzler, MD

Blood (2016) 128 (22): 5414.

https://doi.org/10.1182/blood.V128.22.5414.5414

Published: 2016

Journal Articles

Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome

Blood (2016) 128 (2): 227–238.

https://doi.org/10.1182/blood-2015-11-685024

Published: 2016

Includes: Supplemental data

Journal Articles

Pediatric chronic myeloid leukemia is a unique disease that requires a different approach

Nobuko Hijiya, Kirk R. Schultz, Markus Metzler, Frederic Millot, Meinolf Suttorp

Blood (2016) 127 (4): 392–399.

https://doi.org/10.1182/blood-2015-06-648667

Published: 2016

Journal Articles

Hyperactive mTOR Pathway Promotes Lymphoproliferation and Abnormal Differentiation in Human Autoimmune Lymphoproliferative Syndrome

Blood (2015) 126 (23): 1020.

https://doi.org/10.1182/blood.V126.23.1020.1020

Published: 2015

Journal Articles

Spleen Size at Diagnosis and Genomic BCR-ABL1 Breakpoint Distribution Differ Age-Dependently in Pediatric Patients with Chronic Myeloid Leukemia (CML)

Meinolf Suttorp, MD PhD, Josephine Tabea Tauer, PhD, Manuela Krumbholz, PhD, Markus Metzler, MD PhD

Blood (2015) 126 (23): 4827.

https://doi.org/10.1182/blood.V126.23.4827.4827

Published: 2015

Journal Articles

Decisions Taken in Children and Adolescents with Chronic Myeloid Leukemia (CML) at Failure of Imatinib Treatment

Meinolf Suttorp, Prof. Dr., Josephine Tabea Tauer, PhD, Manuela Krumbholz, PhD, Nils von Neuhoff, PhD, Brigitte Schlegelberger, MD, Markus Metzler, Prof. Dr., Christian Thiede, MD, all Participants of Trial CML-PAED II

Blood (2014) 124 (21): 1798.

https://doi.org/10.1182/blood.V124.21.1798.1798

Published: 2014

NARROW

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience

Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML

Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response

Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation

The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13

High Platelet Counts, Thrombosis, Bleeding Signs, and Acquired Von Willebrand Syndrome at Diagnosis of Pediatric Chronic Myeloid Leukemia

Vaccination with Live Attenuated Virus Vaccines in Four Pediatric Patients with CML While on Imatinib Treatment

The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression

The preleukemic TCF3 -PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Nivolumab As Salvage Therapy in Pediatric Patients with Relapsed and Refractory Lymphomas

Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome

Pediatric chronic myeloid leukemia is a unique disease that requires a different approach

Hyperactive mTOR Pathway Promotes Lymphoproliferation and Abnormal Differentiation in Human Autoimmune Lymphoproliferative Syndrome

Spleen Size at Diagnosis and Genomic BCR-ABL1 Breakpoint Distribution Differ Age-Dependently in Pediatric Patients with Chronic Myeloid Leukemia (CML)

Decisions Taken in Children and Adolescents with Chronic Myeloid Leukemia (CML) at Failure of Imatinib Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only